Advertisement

Topics

Teva, Mylan Seen to Stay on M&A Sidelines

11:00 EDT 5 Aug 2017 | Topix

Teva is 'in no shape' to be making acquisitions while Mylan is 'still pretty leveraged,' says Oppenheimer analyst Derek Archila. Teva Pharmaceutical Industries Ltd. and Mylan NV will probably stay on the M&A sidelines, according to Oppenheimer & Co.

Original Article: Teva, Mylan Seen to Stay on M&A Sidelines

NEXT ARTICLE

More From BioPortfolio on "Teva, Mylan Seen to Stay on M&A Sidelines"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.